<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942860</url>
  </required_header>
  <id_info>
    <org_study_id>WL107</org_study_id>
    <nct_id>NCT04942860</nct_id>
  </id_info>
  <brief_title>The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo</brief_title>
  <acronym>EVRAM</acronym>
  <official_title>The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolaus Copernicus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicolaus Copernicus University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the influence of two concentrations of methotrexate on&#xD;
      vitiligous lesions in patients with non-segmental vitiligo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methotrexate, synthesized in the 1950s as an anticancer drug with an antiproliferative&#xD;
      effect, is currently one of the most commonly used immunosuppressive agents in dermatology.&#xD;
      The use of small, non-oncological doses has revealed its anti-inflammatory properties,&#xD;
      including the impact on a number of cytokines involved in the pathogenesis of autoimmune&#xD;
      diseases. It has been shown that treatment with methotrexate reduces the levels of&#xD;
      TNF-alpha-producing T cells, while the number of IL-10 producing T cells increases.&#xD;
      Methotrexate also inhibits the synthesis of interferon-γ. The above considerations justify&#xD;
      the use of topical methotrexate in patients with vitiligo in order to obtain repigmentation.&#xD;
&#xD;
      A study has been designed as a single-center, randomized, double-blind, placebo-controlled&#xD;
      pilot study with the enrollment of up to 100 active non-segmental vitiligo patients&#xD;
      presenting with vitiligous lesions on both upper and lower limbs. Clinical effects of gel&#xD;
      containing 1% methotrexate or 0.5% methotrexate applied on a preselected limb will be&#xD;
      assessed in comparison with vehicle ointment applied on the opposite limb. All study&#xD;
      participants will undergo clinical evaluation using Body Surface Area (BSA) and Vitiligo Area&#xD;
      Scoring Index (VASI) scales at baseline, week 4, week 8 and week 12 time points. Precise&#xD;
      assessment of skin lesions will be performed using photographic documentation obtained during&#xD;
      each study visit and processed with NIS-Elements software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of repigmentation of vitiligous lesions achieved after the administration of 1% methotrexate or 0.5% methotrexate gels compared to vehicle gel after a 12-week study period</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from baseline in repigmentation on BSA scale at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluation of repigmentation of vitiligous lesions achieved after the administration of 1% methotrexate or 0.5% methotrexate gels compared to vehicle gel after a 12-week study period</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from baseline in repigmentation on VASI scale at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who achieved particular response rate as follows none 0%; poor 1-25%; moderate 26-50%; good 51-75%; excellent &gt;75% in each arm assessed as a relative reduction in BSA scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of: poor 1-25%; moderate 26-50%; good 51-75%; excellent &gt;75% responders in each arm assessed as a relative reduction in BSA scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who achieved particular response rate as follows none 0%; poor 1-25%; moderate 26-50%; good 51-75%; excellent &gt;75% in each arm assessed as a relative reduction in VASI scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of: poor 1-25%; moderate 26-50%; good 51-75%; excellent &gt;75% responders in each arm assessed as a relative reduction in VASI scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of 1% methotrexate and 0.5% methotrexate gel efficacy between study participants</measure>
    <time_frame>12 weeks</time_frame>
    <description>comparison of BSA scale change between study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of 1% methotrexate and 0.5% methotrexate gel efficacy between study participants</measure>
    <time_frame>12 weeks</time_frame>
    <description>comparison of VASI scale change between study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the association between disease duration and repigmentation rate in study arms</measure>
    <time_frame>12 weeks</time_frame>
    <description>the association between disease duration and repigmentation rate in study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of adverse events during treatment as assessed by CTCAE v4.0</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of adverse events related to study treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-segmental Vitiligo</condition>
  <arm_group>
    <arm_group_label>Methotrexate 1% gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% methotrexate gel applied onto a predefined limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate 0.5% gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% methotrexate gel applied onto a predefined limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel applied onto a predefined limb</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Methotrexate gel</intervention_name>
    <description>1% methotrexate gel applied onto a predefined limb</description>
    <arm_group_label>Methotrexate 1% gel</arm_group_label>
    <arm_group_label>Vehicle gel</arm_group_label>
    <other_name>methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Methotrexate gel</intervention_name>
    <description>0.5% methotrexate gel applied onto a predefined limb</description>
    <arm_group_label>Methotrexate 0.5% gel</arm_group_label>
    <arm_group_label>Vehicle gel</arm_group_label>
    <other_name>methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of Clinic of Dermatology, Sexually Transmitted Diseases and&#xD;
             Immunodermatology, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz&#xD;
&#xD;
          2. Provision of an informed consent form prior to any study procedures&#xD;
&#xD;
          3. Diagnosis of non-segmental acrofacial vitiligo with upper and lower limbs involvement&#xD;
&#xD;
          4. Active vitiligo, defined as appearance of new areas of depigmentation or progression&#xD;
             of existing areas of depigmentation within 3 months preceding screening&#xD;
&#xD;
          5. Male or non-pregnant and non-breastfeeding female patients aged 18 to 80 years&#xD;
&#xD;
          6. Women must use effective contraception one month preceding treatment, during treatment&#xD;
             and 6 months after completing treatment.&#xD;
&#xD;
          7. Confirmed valid health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of segmental, mixed, unclassified or undefined vitiligo&#xD;
&#xD;
          2. Pregnancy and breastfeeding&#xD;
&#xD;
          3. Hypersensitivity to methotrexate or any of the excipients&#xD;
&#xD;
          4. Systemic immunosuppressive/immunomodulating i.e. cyclosporine A, corticosteroids&#xD;
             within 4 weeks preceding eligibility screening or azathioprine, methotrexate,&#xD;
             mycophenolate mofetil, Janus kinase - JAK within 8 weeks preceding eligibility&#xD;
             screening&#xD;
&#xD;
          5. Phototherapy due to vitiligo or any other medical conditions within the 4-week period&#xD;
             preceding eligibility screening&#xD;
&#xD;
          6. Any topical or systemic additional vitiligo treatment (e.g. antioxidants, ginkgo&#xD;
             biloba, dermo-cosmetics) within 4 weeks preceding screening&#xD;
&#xD;
          7. Surgical treatment of vitiligous lesions within past 4 weeks&#xD;
&#xD;
          8. Severe liver dysfunction [bilirubin&gt; 5 mg / dL (85.5 μmol / L)], including cirrhosis&#xD;
             and hepatitis&#xD;
&#xD;
          9. Severe renal impairment (eGFR &lt;20 ml / min),&#xD;
&#xD;
         10. Disorders of the hematopoietic system, bone marrow disorders (leukopenia,&#xD;
             thrombocytopenia, anemia),&#xD;
&#xD;
         11. Immunodeficiencies, including HIV infection&#xD;
&#xD;
         12. Severe acute or chronic infections such as tuberculosis&#xD;
&#xD;
         13. Alcohol abuse&#xD;
&#xD;
         14. Mouth ulcers and known active gastric or duodenal ulcer disease&#xD;
&#xD;
         15. Recent surgical wounds.&#xD;
&#xD;
         16. Skin malignancies (currently or history of skin malignancy within 5 years preceding&#xD;
             screening)&#xD;
&#xD;
         17. Presence of skin characteristics that may interfere with study assessments&#xD;
&#xD;
         18. Patients currently participating in any other clinical study&#xD;
&#xD;
         19. Uncooperative patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafał Czajkowski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Chair and Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Medical College in Bydgoszcz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Cichewicz, MD</last_name>
    <phone>+48 52585 4568</phone>
    <email>adam.cichewicz@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Nicolaus Copernicus University, Faculty of Medicine in Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Cuiavian-Pomeranian</state>
        <zip>85094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafał Czajkowski, Prof.</last_name>
      <phone>+48 52585 4568</phone>
      <email>r.czajkowski@cm.umk.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nicolaus Copernicus University</investigator_affiliation>
    <investigator_full_name>Rafal Czajkowski</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

